Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Ipilimumab

4

I.a Pneumonitis (ILD), acute and/or severe (may cause ARDS)

1
Last update : 19/10/2014
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
CTLA4 blocking immunotherapy
3
Immune checkpoint inhibitors (ICI) - ICI combinatorial Rx
5
Tremelimumab
1

Publications

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.
British journal of cancer 2016 May 10;114;1084-9 2016 May 10
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
The New England journal of medicine 2015 May 21;372;2006-17 2015 May 21
Severe acute respiratory distress syndrome due to ipilimumab.
The European respiratory journal 2013 Sep;42;866-8 2013 Sep
CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation.
Blood 2009 Feb 12;113;1581-8 2009 Feb 12

Powered by

  • ^
  • Contact
  • Cookies
  • About

The Pneumotox website uses cookies. By accessing or using our website, you consent to the collection, use and disclosure of the garnered information in accordance with our privacy policy.

Learn more about cookies